- |||||||||| memantine / generics
Journal: Regulation of Excitatory Amino Acid Transmission in the Retina: Studies on Neuroprotection. (Pubmed Central) - Oct 30, 2019
Therefore, it is feasible that several pathways are involved in protecting the retina from toxic insults in ocular neurodegenerative conditions such as glaucoma and retinal ischemia. Furthermore, these experimental models are viable tools for evaluating therapeutic candidates in ocular neuropathies.
- |||||||||| memantine / generics
Journal: Development of a dynamic physiologically-based mechanistic kidney model to predict renal clearance. (Pubmed Central) - Oct 29, 2019
The feasibility of incorporating active secretion and pH-dependent bidirectional passive diffusion into the model was demonstrated using PAH, cimetidine, memantine, and salicylic acid. The developed model enables simulation of renal clearance from in vitro permeability data, with predicted renal clearance within 2-fold for 87% of the test drugs.
- |||||||||| memantine / generics
Journal: Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. (Pubmed Central) - Oct 27, 2019
Deprescribing ChEIs and memantine through shared decision making with individuals and their caregivers by: ▶determining their treatment goals; ▶discussing benefits and harms of continuing and ceasing medication, from the start of therapy and throughout; and ▶engaging them in monitoring after discontinuation, while informing carers that the individual will continue to decline after discontinuation. This approach may reduce adverse drug reactions and medication burden, leading to improved quality of life in people with dementia.
- |||||||||| memantine / generics
Journal: The use of memantine in neuropsychiatric disorders: An overview. (Pubmed Central) - Oct 24, 2019
There is not enough evidence to support the use of antipsychotics or stimulants in treating CAMC. Memantine may have several therapeutic applications in psychiatry, reflecting the involvement of glutamate pathways in multiple psychiatric disorders.
- |||||||||| memantine / Generic mfg.
Journal: Radiation induces age-dependent deficits in cortical synaptic plasticity. (Pubmed Central) - Oct 20, 2019
Pretreatment with memantine offered protection to both juvenile and adult animals. Deficits in cortical plasticity may contribute to radiation-induced cognitive dysfunction, including deficits in attention and age-dependent sensitivity of such pathways, which may underlie differences in clinical outcomes between juveniles and adults after cranial irradiation.
- |||||||||| donepezil / Generic mfg., memantine / Generic mfg.
REPURPOSING IGMESINE FOR THE TREA TMENT OF NEURODEGENERATIVE DISEASES. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_311;
Very interesting synergistic e ects were also found with ibuprofen, atorvastatine and selegiline, but not memantine... These encouraging preclinical results prompt us to evaluate the e cacy of igmesine in Phase 2A trials in human.
- |||||||||| lithium / generics, memantine / generics
Lithium Sarcosine Delays Disease Onset, Prolongs Survival and Reduces Neurological Deficits in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis by Its Synergistic Dual Therapeutic Mechanisms (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_1103;
Drugs such as riluzole and memantine which delay the disease progression and prolong the life span of SOD1-G93A mice while attenuate NMDA activity...Moreover, lithium sarcosine displayed better rescue/protective effects on MK801-induced hyperlocomotion than lithium chloride...However, both lithium carbonate and lithium sarcosine treatments improved the latency in SOD1-G93A mice and the first significant decrease on rotarod performance was observed at 15 and 16 weeks of age, respectively... Overall, lithium sarcosine has superior physicochemical properties and delays disease onset, prolongs survival and reduces neurological deficits presumably due to its synergistic dual therapeutic mechanisms
- |||||||||| donepezil / generics, galantamine hydrobromide / generics, memantine / generics
The Investigation of Symptoms in Alzheimers Disease: Toward Optimal Strategies of Treatment for the Disease (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_956;
BPSD are worse in the middle stages than those in the early stages, but controllable by the treatment. To inhibit decreasing of cognitive function in AD, and thus to prevent occurrence of BPSD and aggravation of ADL, it is critical to maintain initial good cognitive function as much as possible, besides early detection of AD and initiation of the treatment.
- |||||||||| memantine / generics
Memantine Effects on EEG Measures of Putative Cortical Excitatory / Inhibitory (E/I) Balance in Schizophrenia (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_609;
Findings confirmed deficient E/I balance in antipsychotic-medicated SZ patients that were normalized by acute administration of memantine (20 mg). Future studies may identify symptomatic or neurocognitive profiles predicting greatest memantine E/I sensitivity; conceivably, such a predictive metric may distinguish subgroups of patients who will most benefit from memantine augmentation therapy.
- |||||||||| memantine / generics
Memantine Enhances Measures of Auditory Fidelity and Learning in Schizophrenia (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_336;
Ongoing studies will assess the “pathway” responsible for these memantine-induced changes in auditory performance measures. Perhaps more importantly, memantine-induced gains in auditory learning may provide a basis for pharmacologic augmentation of the pro-cognitive effects of auditory-based targeted cognitive training (TCT).
- |||||||||| GRF6019 / Alkahest, Grifols, memantine / Generic mfg.
A PHASE 2 TRIAL OF GRF6019 IN MILD-TO- MODERATE ALZHEIMER’S DISEASE. () - Oct 16, 2019 - Abstract #CTAD2019CTAD_105;
P2
Furthermore, progression of disease in GRF6019- treated subjects was slower than what would be expected in this population. Based on these data, the benefit-risk of continued clinical development of plasma protein fractions in AD is favorable, and a placebo-controlled Phase 2b trial is currently being planned.
- |||||||||| memantine / Generic mfg.
DEVELOPMENT OF GO/NO-GO DECISIONMAKING CRITERIA IN EARLY CLINICAL DEVELOPMENT OF AGENTS TO TREAT ALZHEIMER’S DISEASE () - Oct 16, 2019 - Abstract #CTAD2019CTAD_26;
A thoughtful and robust set of decision-making criteria, specified a priori, can and should be applied under many circumstances. However, the specific criteria for these Go/No Go decisions may differ depending on the context e.g. stage of development, stage of disease, mechanism of action, trial design, competitive landscape and opportunity costs, and must be well tailored to the needs of each program.
- |||||||||| aripiprazole / Generic Mfg., paroxetine / Generic Mfg.
Retrospective data, Review, Journal: Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. (Pubmed Central) - Oct 16, 2019
On the basis of the limited data available, the best evidence is for the use of aripiprazole, fluoxetine and sodium valproate as augmentation agents for total psychosis symptoms and memantine for negative symptoms. However, these conclusions are tempered by generally short follow-up periods and poor study quality.
- |||||||||| donepezil / generics, galantamine hydrobromide / generics, memantine / generics
Review, Journal, Adverse events: Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects. (Pubmed Central) - Oct 15, 2019
Antidepressant drugs, which inhibit 5-HT reuptake into the nerve terminals, also synergistically augment antipsychotic-induced EPS, while mirtazapine (α, 5-HT and 5-HT antagonist) reduces the EPS induction...Specifically, activation of 5-HT receptors or blockade of 5-HT, 5-HT and 5-HT receptors can alleviate EPS induction both by antipsychotics alone and by combined antipsychotic treatments with ChEIs or 5-HT reuptake inhibitors. In this article, we review antipsychotic use in treating BPSD and discuss the favorable drug selection in terms of the management of antipsychotic-induced EPS.
- |||||||||| memantine / generics
Review, Journal: Drug treatment of Alzheimer's dementia : Status quo and perspectives (Pubmed Central) - Oct 11, 2019
AD is characterized by progressive impairments of memory as well as other cognitive functions and an increasing loss of autonomy in everyday life. This review article provides an overview of the current state-of-the-art (symptomatic) pharmacological treatment of Alzheimer's disease, specifics in the context of concomitant neuropsychiatric symptoms in multimorbid patients, and drugs currently under development that have a potentially causal (disease modifying) effect are also mentioned.
- |||||||||| Journal: France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease. (Pubmed Central) - Oct 10, 2019
The evidence-based medicine related to these drugs reaches a high level in literature, whereas the clinical relevance of these treatments must be considered with co-prescription of psychosocial interventions and related approaches. As no serious pharmacovigilance signal has been provided by health authorities, the ratio of benefits/risks favors these drugs.
- |||||||||| ondansetron / generics, memantine / generics
Journal: Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research. (Pubmed Central) - Oct 4, 2019
Previously untested drugs also deserve attention, especially as recent research has suggested new possible contributors to OCD pathophysiology. Similarly, psychotherapeutic interventions beyond CBT should be investigated, and treatments with preliminary evidence in OCD, including Acceptance Commitment Therapy, Danger Ideation Reduction Therapy, and technology-enabled interventions like computerized CBT and Virtual Reality Exposure Therapy, should be carefully tested.
- |||||||||| memantine / generics
Journal: Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease. (Pubmed Central) - Oct 4, 2019
Furthermore, the currently available pharmacological treatment only provides short-term improvements and is focused on the use of cholinesterase (ChEs) inhibitors or memantine, an approved medicine that is a glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker...The development of multi-target-directed ligands (MTDLs) represents an exciting challenge for organic chemists. As such, recently developed chromone-type compounds have a potential use as MTDLs for the treatment of AD.
- |||||||||| memantine / generics
Review, Journal: Diagnosis and treatment of cognitive impairment. (Pubmed Central) - Sep 30, 2019
The drugs of choice for the symptomatic treatment of cognitive deficits in Alzheimer's disease and Parkinson-associated dementia are cholinesterase inhibitors and memantine; there is no specific pharmacological treatment for other types of dementia. Prevention and treatment of cardiovascular risk factors can potentially retard the progression of possibly all forms of dementia.
- |||||||||| memantine / generics
Journal: Adenosine A Receptors Facilitate Synaptic NMDA Currents in CA1 Pyramidal Neurons. (Pubmed Central) - Sep 28, 2019
Prevention and treatment of cardiovascular risk factors can potentially retard the progression of possibly all forms of dementia. These results show that A Rs exert a positive post-synaptic modulatory effect over synaptic, but not extrasynaptic NMDARs in CA1 neurons and therefore under non-pathological conditions may contribute to shift the dual role of NMDARs towards enhancement of synaptic plasticity.
- |||||||||| memantine / generics
Journal: Endoplasmic reticulum stress contributes to NMDA-induced pancreatic β-cell dysfunction in a CHOP-dependent manner. (Pubmed Central) - Sep 27, 2019
These results show that A Rs exert a positive post-synaptic modulatory effect over synaptic, but not extrasynaptic NMDARs in CA1 neurons and therefore under non-pathological conditions may contribute to shift the dual role of NMDARs towards enhancement of synaptic plasticity. This study confirms that ER stress is actively involved in the activation of NMDARs-related β-cell dysfunction.
- |||||||||| memantine / generics
Journal: Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. (Pubmed Central) - Sep 26, 2019
Finally, when applied topically in a rodent model of ocular hypertension for three weeks, MEM-NP eye drops were found to significantly (p < 0.0001) reduce RGC loss. These results suggest that topical MEM-NP is safe, well tolerated, and, most promisingly, neuroprotective in an experimental glaucoma model.
- |||||||||| memantine / generics
Comparing Cognitive Decline after Radiotherapy for Brain Metastases: A Meta-Analysis of Prospective Trials (ASTRO Innovation Hub) - Sep 24, 2019 - Abstract #ASTRO2019ASTRO_3046;
Stereotactic radiosurgery results in the lowest rate of neurocognitive dysfunction following treatment for brain metastases. In patients with brain metastases who may benefit from WBRT over SRS, WBRT with the addition of memantine and/or hippocampal avoidance is associated with a decreased risk of neurocognitive dysfunction.
|
